title: Predictive value of interim PET/CT in DLBCL treated with R-CHOP: meta-analysis.
abstract: OBJECTIVE
  We conducted a meta-analysis to evaluate the predictive value of interim (18)F-FDG PET/CT in patients with DLBCL treated with R-CHOP chemotherapy.
  
  
  METHODS
  We searched for articles published in PubMed, ScienceDirect, Wiley, Scopus, and Ovid database from inception to March 2014. Articles related to interim PET/CT in patients with DLBCL treated with R-CHOP chemotherapy were selected. PFS with or without OS was chosen as the endpoint to evaluate the prognostic significance of interim PET/CT.
  
  
  RESULTS
  Six studies with a total of 605 cases were included. The sensitivity of interim PET/CT ranged from 21.2% to 89.7%, and the pooled sensitivity was 52.4%. The specificity of interim PET/CT ranged from 37.4% to 90.7%, and the pooled specificity was 67.8%. The pooled positive likelihood ratio and negative likelihood ratio were 1.780 and 0.706, respectively. The explained AUC was 0.6978 and the Q* was 0.6519.
  
  
  CONCLUSIONS
  The sensitivity and specificity of interim PET/CT in predicting the outcome of DLBCL patients treated with R-CHOP chemotherapy were not satisfactory (52.4% and 67.8%, resp.). To improve this, some more work should be done to unify the response criteria and some more research to assess the prognostic value of interim PET/CT with semiquantitative analysis.
authors.affiliation: Department of Nuclear Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.
authors.forename: Na
authors.initials: N
authors.lastname: Sun
authors.affiliation: Department of Nuclear Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.
authors.forename: Jinhua
authors.initials: J
authors.lastname: Zhao
authors.affiliation: Department of Nuclear Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.
authors.forename: Wenli
authors.initials: W
authors.lastname: Qiao
authors.affiliation: Department of Nuclear Medicine, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 200080, China.
authors.forename: Taisong
authors.initials: T
authors.lastname: Wang
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D008297:Male; D064847:Multimodal Imaging / Q000706:statistics & numerical data*; D049268:Positron-Emission Tomography / Q000706:statistics & numerical data*; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D015203:Reproducibility of Results; D000069283:Rituximab; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000706:statistics & numerical data*; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone